Shu-Peng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shu-Peng Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Dong Chen
Institute of Cadio-Cerebrovascular Medicine, Dalian University of Technology, Dalian, China
2 shared publications Bohan Xi
Department of Rehabilitation Beijing Rehabilitation Hospital of Capital Medical University Beijing China
1 shared publicationJia-Ming Huang
Department of Neurosurgery, Central Hospital of Dalian University of Technology, Dalian, China
1 shared publicationJia-Wen Cui
School of Biomedical Engineering, Faculty of Medicine, Dalian University of Technology, Dalian, China
1 shared publicationJiaming Huang
Department of Neurosurgery Affiliated Dalian Municipal Central Hospital Dalian Medical University Dalian China
1 shared publicationJing-Lin Zhao
Department of Cardiology, the Second Hospital of Dalian Medical University, Dalian, China
1 shared publication
Latest Publications
- Open Access
- 9 June 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (3)
Transcarotid Artery Revascularization for Asymptomatic Carotid Stenosis: A Systematic Review and Meta-Analysis
The online version contains supplementary material available at 10.1007/s12975-026-01457-2.
- 9 June 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (3)
Open AccessTranscarotid Artery Revascularization for Asymptomatic Carotid Stenosis: A Systematic Review and Meta-Analysis
The online version contains supplementary material available at 10.1007/s12975-026-01457-2.
- Open Access
- 1 January 2025
- Published by Institution of Engineering and Technology (IET) in IET Systems Biology
- Vol. 19 (1) , e70025
Integration of Single‐Cell RNA and Bulk RNA Sequencing Reveals Cellular Heterogeneity and Identifies Survival‐Associated Regulatory Networks in Glioblastoma
Glioblastoma is a highly aggressive and devastating brain malignancy with dismal prognosis and extremely limited therapeutic options. Identification of prognostic biomarkers and therapeutic targets from multi‐omics data is critical for improving patient outcomes. In this study, we investigated the clinical significance of cellular heterogeneity and super‐enhancer‐driven regulatory networks, which are critically implicated in glioblastoma progression and treatment resistance. We first performed scRNA‐seq to dissect tumour microenvironment heterogeneity, identifying 16 distinct cell clusters, including astrocytes, macrophages, and CD8+ T cells. CellChat analysis revealed key intercellular signalling pathways, with astrocytes and macrophages acting as central communication hubs. To integrate bulk RNA sequencing data, we applied the Scissor algorithm to identify survival‐associated cell states. By combining single‐cell and bulk transcriptomic data, we uncovered 642 survival‐related genes, including QKI and RBM47, which robustly predicted patient survival and immunotherapy response. Furthermore, WGCNA analysis identified seven co‐expression modules and super enhancer‐regulated networks orchestrated by transcription factors (RFX2, RFX4) and hub genes (NEAT1, CFLAR). These networks stratified patients into high‐ and low‐risk groups with significant survival differences. Collectively, our findings elucidate the intricate interplay between cellular heterogeneity and super enhancer‐driven gene regulation in glioblastoma, providing a translational framework for targeting oncogenic hubs and modulating microenvironment interactions.
- 1 January 2025
- Published by Institution of Engineering and Technology (IET) in IET Systems Biology
- Vol. 19 (1) , e70025
Open AccessIntegration of Single‐Cell RNA and Bulk RNA Sequencing Reveals Cellular Heterogeneity and Identifies Survival‐Associated Regulatory Networks in Glioblastoma
Glioblastoma is a highly aggressive and devastating brain malignancy with dismal prognosis and extremely limited therapeutic options. Identification of prognostic biomarkers and therapeutic targets from multi‐omics data is critical for improving patient outcomes. In this study, we investigated the clinical significance of cellular heterogeneity and super‐enhancer‐driven regulatory networks, which are critically implicated in glioblastoma progression and treatment resistance. We first performed scRNA‐seq to dissect tumour microenvironment heterogeneity, identifying 16 distinct cell clusters, including astrocytes, macrophages, and CD8+ T cells. CellChat analysis revealed key intercellular signalling pathways, with astrocytes and macrophages acting as central communication hubs. To integrate bulk RNA sequencing data, we applied the Scissor algorithm to identify survival‐associated cell states. By combining single‐cell and bulk transcriptomic data, we uncovered 642 survival‐related genes, including QKI and RBM47, which robustly predicted patient survival and immunotherapy response. Furthermore, WGCNA analysis identified seven co‐expression modules and super enhancer‐regulated networks orchestrated by transcription factors (RFX2, RFX4) and hub genes (NEAT1, CFLAR). These networks stratified patients into high‐ and low‐risk groups with significant survival differences. Collectively, our findings elucidate the intricate interplay between cellular heterogeneity and super enhancer‐driven gene regulation in glioblastoma, providing a translational framework for targeting oncogenic hubs and modulating microenvironment interactions.